By: Nic Abelian
The pharmaceutical industry continues to face a persistent challenge: economic inefficiencies resulting from disconnected customer experience and data systems. These inefficiencies can contribute to delayed drug launches, reduced margins, and longer time-to-market cycles. According to research studies, the cost of such issues runs in the multi-billion-dollar range annually, highlighting the ongoing need for thoughtful technological improvements. One emerging solution involves Agentic Application Layers—a model that may represent a significant shift for life science companies seeking to modernize their operations and enhance agility. While the model is still evolving, it could offer new pathways for data management, operations, and customer engagement.
For years, life sciences companies have relied on so-called “black box” systems that offer limited transparency into underlying data, workflows, and decision logic. Improzo, a technology startup in the pharma space, is among the companies working to address this challenge. Their approach involves modular access and simplified integration, aiming to help pharmaceutical organizations better align their data, digital tools, and operational ecosystems, while keeping their data within their own environment. Improzo’s Agentic Application Layer, known as iZO, is designed to support a more connected and proactive approach to managing pharma operations, and the company is currently collaborating with several pharma firms interested in alternatives to traditional consulting engagements and siloed analytics systems. These systems are also being developed to support customizable data outputs for use in commercial operations—potentially assisting life science companies to better utilize data assets for strategic purposes.
By centralizing relevant data, automating recurring reports, and enabling self-service BI capabilities, the suite of tools seeks to give internal teams more operational autonomy and enable better decision making. According to Improzo, a key differentiator lies in how their iZO suite of solutions shares real-time information across internal teams—as opposed to static dashboards, which often limit insights to high-level summaries. This design approach may facilitate deeper exploration of actionable insights and more timely decision-making. The broader trend toward interoperable systems is gaining traction in the sector, and Agentic Application Layers like Improzo’s iZO are being positioned as part of that shift—with the goal of increasing agility and responsiveness.
“The ability to unlock data-driven insights combining both quantitative analytics and qualitative contextual insights in near real-time is increasingly important for staying competitive in the pharma sector,” says Jane Urban, Chief Data and Analytics Officer at Improzo. She adds, “Solutions that are designed to leverage aspects of advanced analytics, NLP, generative AI, and agentic AI together allow for the best of each and empower end users to have the potential to improve adoption rates and create measurable value.” The company shared internal benchmarks indicating that a life science organization that adopted parts of this model saw significant improvements in operational efficiency and customer experience outcomes. While these results may vary depending on implementation context, they suggest a possible direction for pharma teams seeking to modernize.
“The concept of Agentic Applications represents a relatively new strategy within the life sciences space. These applications are built to operate with a degree of autonomy—leveraging AI to make intelligent suggestions and respond dynamically to user input or environmental signals, while still allowing for human-in-the-loop visibility,” says Abhishek Trigunait, Chief Technology Officer at Improzo. As more organizations explore their potential, they can contribute to a measured shift in how healthcare systems approach efficiency, transparency, and internal ownership of insights.
A central theme in Improzo’s iZO suite is built-in adaptability. The tools are designed to function within a company’s existing infrastructure, avoiding the need for a complete tech overhaul. The application layer is configurable, allowing teams to activate or deactivate specific tools based on their current needs or changing priorities. According to Jane Urban, who has spent many years as a VP-level leader in pharmaceutical companies before Improzo, this design was intentional. “We wanted to create something that could meet teams where they are today and grow with the organization—not just plug in and replace what’s already there,” she explains.
Security and governance also play a key role. Improzo emphasizes that the iZO suite of solutions operates within the data firewalls of its client organizations, ensuring that proprietary information remains under company control. Features are built in to ensure that only authorized users have access to sensitive datasets, aligning with the industry’s strong emphasis on privacy and compliance.
While results will vary based on implementation, iZO’s structure—built for real-time analytics, customization, and secure internal deployment—could support companies in becoming more proactive and responsive. In a field where slow decision-making can have significant downstream impacts, this adaptability and transparency may become increasingly important.
As Jane Urban puts it, “We’re seeing a broader movement in pharma to reduce the lag between data collection and action. Technologies that help close that gap, even modestly, can deliver incremental wins that add up over time.” She notes that companies adopting modular, user-driven applications might be better positioned to adapt to ongoing changes in regulations, customer expectations, and market dynamics.
The rise of AI-powered, interoperable solutions like Improzo’s iZO reflects a shift in how companies perceive and manage their data assets—not just as repositories of information, but as real-time tools for strategic execution. Though still in its early stages, this approach could prove instrumental in redefining performance metrics in life sciences.
Improzo’s Agentic Application Layer, known as iZO, is just one example of this broader trend. By offering flexible integration, real-time insights, and scalable tools, the company’s suite of applications may help life sciences organizations improve internal decision-making and streamline operations. As adoption increases and more data becomes available, this model has the potential to contribute to better operational visibility, quicker iteration cycles, and more substantial alignment between internal teams.
For more information, visit www.improzo.com.
Connect with Jane Urban, Chief Data and Analytics Officer at Improzo, on LinkedIn: Jane Urban
Connect with Abhishek Trigunait, Chief Technology Officer at Improzo, on LinkedIn: Abhishek Trigunait
Disclaimer: This article is for informational purposes only and does not constitute professional advice. The performance and benefits of Improzo’s solutions may vary depending on individual implementation and organizational context. Readers should conduct their own research and consult with qualified professionals before making decisions based on this content.
